NASDAQ:ATOS - Atossa Genetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.04 -0.19 (-4.49 %) (As of 03/20/2019 04:00 PM ET)Previous Close$4.23Today's Range$3.82 - $4.185052-Week Range$0.80 - $7.56Volume2.01 million shsAverage Volume3.38 million shsMarket Capitalization$22.81 millionP/E RatioN/ADividend YieldN/ABeta3.59 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington. Receive ATOS News and Ratings via Email Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATOS Previous Symbol CUSIPN/A CIK1488039 Webwww.atossagenetics.com Phone206-325-6086Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book1.55Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,120,000.00 Net MarginsN/A Return on Equity-167.87% Return on Assets-101.07%Miscellaneous EmployeesN/A Outstanding Shares5,647,000Market Cap$22.81 million Next Earnings Date3/26/2019 (Estimated) OptionableNot Optionable Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions What is Atossa Genetics' stock symbol? Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS." When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work? Atossa Genetics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc (NASDAQ:ATOS) released its earnings results on Tuesday, November, 13th. The company reported ($0.64) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.01. View Atossa Genetics' Earnings History. When is Atossa Genetics' next earnings date? Atossa Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for Atossa Genetics. What price target have analysts set for ATOS? 2 brokers have issued twelve-month price targets for Atossa Genetics' shares. Their predictions range from $5.00 to $10.00. On average, they anticipate Atossa Genetics' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 85.6% from the stock's current price. View Analyst Price Targets for Atossa Genetics. What is the consensus analysts' recommendation for Atossa Genetics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atossa Genetics. Has Atossa Genetics been receiving favorable news coverage? Press coverage about ATOS stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Atossa Genetics earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. Who are some of Atossa Genetics' key competitors? Some companies that are related to Atossa Genetics include STRATA Skin Sciences (SSKN), iCAD (ICAD), Endologix (ELGX), Apollo Endosurgery (APEN), Titan Medical (TMDI), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Invo Bioscience (IVOB), Motus GI (MOTS), Arch Therapeutics (ARTH), Repro-Med Systems (REPR), Pro-Dex (PDEX), RA Medical Systems (RMED), Avinger (AVGR) and AIT Therapeutics (AITB). What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include Biopharmx (BPMX), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Micron Technology (MU), Heat Biologics (HTBX), Cytori Therapeutics (CYTX) and General Electric (GE). Who are Atossa Genetics' key executives? Atossa Genetics' management team includes the folowing people: Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical AffairsDr. Jack Cuzick, Member of Scientific Advisory Board Who are Atossa Genetics' major shareholders? Atossa Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (1.24%) and Barclays PLC (0.57%). Company insiders that own Atossa Genetics stock include H Lawrence Remmel and Kyle Guse. View Institutional Ownership Trends for Atossa Genetics. Which major investors are buying Atossa Genetics stock? ATOS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Barclays PLC. Company insiders that have bought Atossa Genetics stock in the last two years include H Lawrence Remmel and Kyle Guse. View Insider Buying and Selling for Atossa Genetics. How do I buy shares of Atossa Genetics? Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Atossa Genetics' stock price today? One share of ATOS stock can currently be purchased for approximately $4.04. How big of a company is Atossa Genetics? Atossa Genetics has a market capitalization of $22.81 million. What is Atossa Genetics' official website? The official website for Atossa Genetics is http://www.atossagenetics.com. How can I contact Atossa Genetics? Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected] MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 122 (Vote Outperform)Underperform Votes: 145 (Vote Underperform)Total Votes: 267MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is the return on assets formula?